These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19761101)

  • 21. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
    Kapitza C; Zdravkovic M; Hindsberger C; Flint A
    Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Liraglutide].
    Takahashi T; Odawara M
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide in type 2 diabetes mellitus.
    Baruah MP; Chaudhury T; Sethi BK; Dharmalingam M
    J Indian Med Assoc; 2012 May; 110(5):335-8. PubMed ID: 23360033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
    Marso SP; Poulter NR; Nissen SE; Nauck MA; Zinman B; Daniels GH; Pocock S; Steinberg WM; Bergenstal RM; Mann JF; Ravn LS; Frandsen KB; Moses AC; Buse JB
    Am Heart J; 2013 Nov; 166(5):823-30.e5. PubMed ID: 24176437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 36. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
    Perry CM
    Drugs; 2011 Dec; 71(17):2347-73. PubMed ID: 22085389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
    Vilsbøll T; Brock B; Perrild H; Levin K; Lervang HH; Kølendorf K; Krarup T; Schmitz O; Zdravkovic M; Le-Thi T; Madsbad S
    Diabet Med; 2008 Feb; 25(2):152-6. PubMed ID: 18201212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.